➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
McKesson
Merck
AstraZeneca

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00405912 St. John's Wort for Tobacco Cessation Completed National Cancer Institute (NCI) Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC NCT00405912 St. John's Wort for Tobacco Cessation Completed Mayo Clinic Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
New Formulation NCT00640159 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed Baylor College of Medicine Phase 4 2007-01-01 Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000276 Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated National Institute on Drug Abuse (NIDA) Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated VA Connecticut Healthcare System Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated Yale University Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Intervention Trials
Schizophrenia 96
Parkinson's Disease 66
Parkinson Disease 62
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Intervention Trials
Parkinson Disease 154
Schizophrenia 102
Disease 73
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Location Trials
United States 834
Canada 75
Germany 55
France 51
United Kingdom 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Location Trials
New York 74
California 69
Maryland 66
Massachusetts 50
Connecticut 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 4 176
Phase 3 121
Phase 2/Phase 3 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 416
Recruiting 173
Not yet recruiting 134
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Sponsor Trials
National Institute on Drug Abuse (NIDA) 60
National Institute of Mental Health (NIMH) 39
Yale University 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Sponsor Trials
Other 1109
Industry 199
NIH 175
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Medtronic
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.